Baseline Q waves as a prognostic modulator in patients with ST-segment elevation: Insights from the PLATO trial

CMAJ. Canadian Medical Association Journal

Volumn 184, Issue 10, 2012, Pages 1135-1142

  Siha, Hany ^a   Das, Debraj ^a   Fu, Yuling ^a   Zheng, Yinggan ^a   Westerhout, Cynthia M ^a   Storey, Robert F ^b   James, Stefan ^c   Wallentin, Lars ^c   Armstrong, Paul W ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c UPPSALA CLINICAL RESEARCH CENTER   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; AGED; ARTICLE; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE MARKER; ELECTROCARDIOGRAM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PROGNOSIS; Q WAVE; SEX DIFFERENCE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION;

EID: 84863646262     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.111683     Document Type: Article

References (11)

1. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: A report of the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). J Am Coll Cardiol 2004;44:671-719.
2. Armstrong PW, Westerhout CM, Welsh RC. Duration of symptoms is the key modulator of the choice of reperfusion for ST-elevation myocardial infarction. Circulation 2009;119:1293-303.
3. Andrews J, French JK, Manda SOM, et al. New Q-waves on the presenting electrocardiogram independently predict increased cardiac mortality following a first ST-elevation myocardial infarction. Eur Heart J 2000;21:647-53.
4. Wong CK, Gao W, Raffel OC, et al. Initial Q-waves accompanying ST-segment elevation at presentation of acute myocardial infarction and 30-day mortality in patients given streptokinase therapy: an analysis from HERO-2. Lancet 2006;367: 2061-7.
5. APEX-AMI Investigators, Armstrong PW, Granger CB, et al. Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial. JAMA 2007;297:43-51.
6. Armstrong PW, Fu Y, Westerhout CM, et al. Baseline Q-wave surpasses time from symptom onset as a prognostic marker in ST-segment elevation myocardial infarction patients treated with primary percutaneous coronary intervention. J Am Coll Cardiol 2009; 53:1503-9.
7. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361:1045-57.
8. James S, Akerblom A, Cannon CP, et al. Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J 2009; 157: 599-605.
9. Anderson WD, Wagner NB, Lee KL, et al. Evaluation of a QRS scoring system for estimating myocardial size. VI: identification of screening criteria for non-acute myocardial infarcts. Am J Cardiol 1988;61:729-33.
10. Schröder R, Wegscheider K, Schröder K, et al. Extent of early ST segment elevation resolution: a strong predictor of outcome in patients with acute myocardial infarction and a sensitive measure to compare thrombolytic regimens. A substudy of the International Joint Efficacy Comparison of Thrombolytics (INJECT) trial. J Am Coll Cardiol 1995;26:1657-64.
11. Lee KL, Woodlief LH, Topol EJ, et al. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Circulation 1995;91:1659-68.